ATXS Astria Therapeutics Inc
- 11.540
- +0.220+1.94%
Astria Therapeutics Inc News
LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $25
Astria Therapeutics Analyst Ratings
H.C. Wainwright Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $16
Evercore Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $25
TD Cowen Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $35
Evercore Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Raises Target Price to $25
A Quick Look at Today's Ratings for Astria Therapeutics Inc(ATXS.US), With a Forecast Between $16 to $35
A Quick Look at Today's Ratings for Astria Therapeutics Inc(ATXS.US), With a Forecast Between $16 to $35
Astria Therapeutics Price Target Maintained With a $22.00/Share by Wedbush
Astria Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $16 Price Target
Astria Therapeutics Price Target Announced at $35.00/Share by TD Cowen
Astria Therapeutics Analyst Ratings
TD Cowen Initiates Astria Therapeutics Inc(ATXS.US) With Buy Rating, Announces Target Price $35
Astria Therapeutics Analyst Ratings
Oppenheimer: The Astria Therapeutics (ATXS.US) rating was maintained, and the target price was adjusted from better than market to better than market, and the target price was adjusted from $29.00 to $25.00.
HC Wainwright & Co. : The Astria Therapeutics (ATXS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $16.00.
Astria Therapeutics Analyst Ratings
Wedbush Reiterates Outperform on Astria Therapeutics, Maintains $22 Price Target
Astria Therapeutics Analyst Ratings
Analysis
Price Target
No Data
No Data